News & Updates

Show Multimedia Only
Maximal androgen blockade the prime prostate cancer treatment option in older patients

Maximal androgen blockade the prime prostate cancer treatment option in older patients

16 Sep 2022

Among prostate cancer patients aged ≥75 years, maximal androgen blockage (MAB) appears to be the most common treatment option, reports a new South Korea study. Meanwhile, the combination of leuprolide and bicalutamide is the most common MAB regimen.

16 Sep 2022
Bladder-directed heated chemotherapy of no clear benefit in NMIBC Bladder-directed heated chemotherapy of no clear benefit in NMIBC

Bladder-directed heated chemotherapy of no clear benefit in NMIBC

12 Sep 2022 byTristan Manalac

In patients with intermediate-risk nonmuscle-invasive bladder cancer (NMIBC), intravesical chemohyperthermia (CHT) does not translate to better cancer control than standard room-temperature chemotherapy, according to a recent phase II study HIVEC-II.

12 Sep 2022
Tension-free vaginal tape for stress incontinence safe, effective in long term

Tension-free vaginal tape for stress incontinence safe, effective in long term

05 Sep 2022

Among women with stress urinary incontinence, the retropubic tension-free vaginal tape (TVT) retains its efficacy up to 24 years after initial placement, with adverse effects being uncommon and having a low impact on quality of life, according to a study.

05 Sep 2022